Publication
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide
| dc.contributor.author | Muzzi, Alessandro | |
| dc.contributor.author | Brozzi, Alessandro | |
| dc.contributor.author | Serino, Laura | |
| dc.contributor.author | Bodini, Margherita | |
| dc.contributor.author | Abad, Raquel | |
| dc.contributor.author | Caugant, Dominique | |
| dc.contributor.author | Comanducci, Maurizio | |
| dc.contributor.author | Lemos, Ana Paula | |
| dc.contributor.author | Gorla, Maria Cecilia | |
| dc.contributor.author | Křížová, Pavla | |
| dc.contributor.author | Mikula, Claudia | |
| dc.contributor.author | Mulhall, Robert | |
| dc.contributor.author | Nissen, Michael | |
| dc.contributor.author | Nohynek, Hanna | |
| dc.contributor.author | Simões, Maria João | |
| dc.contributor.author | Skoczyńska, Anna | |
| dc.contributor.author | Stefanelli, Paola | |
| dc.contributor.author | Taha, Muhamed-Kheir | |
| dc.contributor.author | Toropainen, Maija | |
| dc.contributor.author | Tzanakaki, Georgina | |
| dc.contributor.author | Vadivelu-Pechai, Kumaran | |
| dc.contributor.author | Watson, Philip | |
| dc.contributor.author | Vazquez, Julio A. | |
| dc.contributor.author | Rajam, Gowrisankar | |
| dc.contributor.author | Rappuoli, Rino | |
| dc.contributor.author | Borrow, Ray | |
| dc.contributor.author | Medini, Duccio | |
| dc.date.accessioned | 2020-05-09T15:15:10Z | |
| dc.date.available | 2020-05-09T15:15:10Z | |
| dc.date.issued | 2019-02-08 | |
| dc.description.abstract | Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates. | pt_PT |
| dc.description.sponsorship | This work was supported by GlaxoSmithKline Biologicals SA,including all costs associated with the development and publishingof the manuscript. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Vaccine. 2019 Feb 8;37(7):991-1000. doi: 10.1016/j.vaccine.2018.12.061. Epub 2019 Jan 17 | pt_PT |
| dc.identifier.doi | 10.1016/j.vaccine.2018.12.061 | pt_PT |
| dc.identifier.issn | 0264-410X | |
| dc.identifier.uri | http://hdl.handle.net/10400.18/6634 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier/ GlaxoSmithKline Biologicals SA. | pt_PT |
| dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0264410X19300325?via%3Dihub | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | 4CMenB Vaccine | pt_PT |
| dc.subject | Genotyping | pt_PT |
| dc.subject | Neisseria meningitidis Serogroup B | pt_PT |
| dc.subject | Strain Coverage | pt_PT |
| dc.subject | gMATS | pt_PT |
| dc.subject | Infecções Respiratórias | pt_PT |
| dc.title | Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1000 | pt_PT |
| oaire.citation.issue | 7 | pt_PT |
| oaire.citation.startPage | 991 | pt_PT |
| oaire.citation.title | Vaccine | pt_PT |
| oaire.citation.volume | 37 | pt_PT |
| rcaap.embargofct | De acordo com o editor online da revista. | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 1-s2.0-S0264410X19300325-main.pdf
- Size:
- 2.59 MB
- Format:
- Adobe Portable Document Format
